Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
Tuesday, November 11, 2025
On November 11, 2025, Shilpa Pharma Lifesciences announced that it has been awarded the highly coveted EcoVadis Gold Medal for its exceptional sustainability performance, making it one of the top-rated pharmaceutical manufacturers not only in Asia but on the global stage. The EcoVadis assessment, which evaluates more than 100,000 companies worldwide, is considered a benchmark for corporate social responsibility, encompassing environmental, labor, ethics, and sustainable procurement criteria. Only the top five percent of evaluated companies receive Gold-level recognition, underscoring Shilpa Pharma Lifesciences' significant achievements in corporate responsibility.
The EcoVadis rating system is renowned within the B2B pharmaceutical manufacturing sector for its rigorous analysis of a company's sustainable practices. Shilpa Pharma Lifesciences was evaluated across several key areas, including environmental management—such as emissions reduction, waste management, and responsible water usage—social impact, labor conditions, fair business ethics, and sustainable procurement. The company established new industry standards by introducing comprehensive environmental management plans, deploying technology-driven waste minimization protocols, and pursuing robust employee skill development programs to ensure worker well-being and company-wide ethical compliance. This recognition will further elevate the company's standing among multinational clients, regulatory authorities, and technology partners across Asia and Europe, reinforcing its commitment to sustainable manufacturing best practices and supply chain excellence.
The award strengthens Shilpa Pharma Lifesciences' value proposition as a preferred contract development and manufacturing organization (CDMO) for global and regional pharmaceutical brands. Over the last year, the company invested significantly in advanced manufacturing automation, energy-efficient infrastructure, and traceability solutions for raw materials, all in alignment with global environmental, social, and governance (ESG) goals. Additionally, Shilpa Pharma Lifesciences has engaged proactively with innovation partners and regional authorities to share best practices for green chemistry, digital transformation in supply chain logistics, and enhanced transparency in supplier qualifications. These measures, supported by the EcoVadis assessment outcomes, illustrate the company's ability to adapt to evolving regulatory frameworks in key Asian markets and its ambition to stay ahead of tightening sustainability requirements across the pharmaceutical industry.
The recognition holds particular significance within the Asian business-to-business pharmaceutical ecosystem, where investor interest, public health authorities, and regulatory scrutiny over sustainability practices continue to increase. Achieving EcoVadis Gold Medal status communicates to stakeholders—including pharma executives, R&D partners, generics manufacturers, and healthcare regulators—that Shilpa Pharma Lifesciences meets and exceeds strict international benchmarks for responsible operations. This also positions the company as a knowledge partner for regional industry events and alliances focused on climate risk mitigation, pandemic preparedness, and circular economy initiatives within pharmaceutical production. In the context of a rapidly evolving landscape for ESG reporting and consumer-facing regulations, the Gold Medal acts as both a competitive differentiator and an invitation to potential collaborators seeking alignment with globally validated sustainability leaders.
Looking ahead, Shilpa Pharma Lifesciences plans to leverage this latest milestone to drive further innovation in sustainable manufacturing, deploy advanced digital tracking for supply chain decarbonization, and expand its partnerships with like-minded organizations and public health agencies. This aligns with broad sectoral trends observed throughout Asia, where pharmaceutical suppliers, active pharmaceutical ingredient (API) manufacturers, and drug product exporters are striving to embrace responsible business standards to enhance international market access. With this achievement, Shilpa Pharma Lifesciences not only sets itself apart as a beacon of responsible business practice but also signals its continued readiness to lead the transformation toward a greener, more resilient future for the Asian pharmaceutical industry.
